Loading...
Loading...
CRMD| Name | Value |
|---|---|
| Revenues | 11.5B |
| Cost of Revenue | 0.7B |
| Gross Profit | 10.8B |
| Operating Expense | 0.6B |
| Operating I/L | -3.3B |
| Other Income/Expense | 0.5B |
| Interest Income | 0.6B |
| Pretax | -2.8B |
| Income Tax Expense | -0.0B |
| Net Income/Loss | -2.8B |
CorMedix Inc. is a biopharmaceutical company specializing in the development and commercialization of therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Its lead product candidate, DefenCath/Neutrolin, is designed to reduce and prevent catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. The company generates revenue through the sale of its anti-infective solution and focuses on addressing the critical need for effective infection prevention in healthcare settings.
